Allergan PLC. (NYSE:AGN) Position Boosted by Boltwood Capital Management
Boltwood Capital Management boosted its position in shares of Allergan PLC. (NYSE:AGN) by 12.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,390 shares of the company’s stock after buying an additional 475 shares during the period. Boltwood Capital Management’s holdings in Allergan PLC. were worth $1,067,000 at the end of the most recent reporting period.
Several other large investors have also recently added to or reduced their stakes in AGN. Veritas Asset Management LLP purchased a new stake in Allergan PLC. during the first quarter worth about $761,339,000. Edgewood Management LLC raised its position in Allergan PLC. by 7.0% in the first quarter. Edgewood Management LLC now owns 2,704,211 shares of the company’s stock valued at $646,090,000 after buying an additional 178,055 shares in the last quarter. Epoch Investment Partners Inc. raised its position in Allergan PLC. by 3.8% in the first quarter. Epoch Investment Partners Inc. now owns 2,013,415 shares of the company’s stock valued at $481,045,000 after buying an additional 73,081 shares in the last quarter. UBS Asset Management Americas Inc. raised its position in Allergan PLC. by 0.3% in the first quarter. UBS Asset Management Americas Inc. now owns 1,995,281 shares of the company’s stock valued at $476,713,000 after buying an additional 5,042 shares in the last quarter. Finally, Blue Ridge Capital L.L.C. raised its position in Allergan PLC. by 24.1% in the first quarter. Blue Ridge Capital L.L.C. now owns 1,909,900 shares of the company’s stock valued at $456,313,000 after buying an additional 370,400 shares in the last quarter. Institutional investors and hedge funds own 83.63% of the company’s stock.
Allergan PLC. (AGN) traded up 0.32% during mid-day trading on Monday, hitting $233.63. 510,883 shares of the company traded hands. Allergan PLC. has a one year low of $184.50 and a one year high of $256.80. The company’s 50-day moving average is $245.93 and its 200-day moving average is $238.13. The stock has a market capitalization of $78.10 billion, a price-to-earnings ratio of 7.12 and a beta of 1.16.
Allergan PLC. (NYSE:AGN) last announced its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.95 by $0.07. The company had revenue of $4.01 billion during the quarter, compared to analysts’ expectations of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. Allergan PLC.’s quarterly revenue was up 8.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.35 earnings per share. Analysts predict that Allergan PLC. will post $16.27 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be given a $0.70 dividend. The ex-dividend date is Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.20%. Allergan PLC.’s payout ratio is presently 9.95%.
Several research analysts have weighed in on AGN shares. Zacks Investment Research upgraded shares of Allergan PLC. from a “hold” rating to a “buy” rating and set a $270.00 price objective on the stock in a research note on Tuesday, July 11th. Goldman Sachs Group, Inc. (The) lowered shares of Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 price objective on the stock. in a research note on Wednesday, May 10th. Sanford C. Bernstein reiterated an “outperform” rating on shares of Allergan PLC. in a research note on Thursday, May 25th. Royal Bank Of Canada upped their price objective on shares of Allergan PLC. from $279.00 to $284.00 and gave the company an “outperform” rating in a research note on Wednesday, May 10th. Finally, Deutsche Bank AG reiterated a “buy” rating and issued a $273.00 price objective (up previously from $265.00) on shares of Allergan PLC. in a research note on Monday, July 17th. Eight investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $275.49.
In other news, Director Nesli Basgoz sold 1,889 shares of the business’s stock in a transaction dated Thursday, May 18th. The shares were sold at an average price of $220.45, for a total value of $416,430.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.36% of the company’s stock.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.